1. First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study. (5th February 2020) Authors: Amrane, Karim; Geier, Margaux; Corre, Romain; Léna, Hervé; Léveiller, Guillaume; Gadby, Florence; Lamy, Régine; Bizec, Jean‐Louis; Goarant, Eric; Robinet, Gilles; Gouva, Sylvie; Quere, Gilles; Abgral, Ronan; Schick, Ulrike; Bernier, Cyril; Chouaid, Christos; Descourt, Renaud Journal: Cancer medicine Issue: Volume 9:Number 7(2020) Page Start: 2309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗